GSK, Exelixis Expedite Review Of Lead MET Inhibitor

Exelixis has agreed to let its partner review XL880 ahead of proof-of-concept to determine whether to pursue commercialization.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet